KR20110128898A - Ｔｒｐａ1 조절자로서 푸로피리미딘디온 유도체 - Google Patents

Ｔｒｐａ1 조절자로서 푸로피리미딘디온 유도체 Download PDF

Info

Publication number
KR20110128898A
KR20110128898A KR1020117022604A KR20117022604A KR20110128898A KR 20110128898 A KR20110128898 A KR 20110128898A KR 1020117022604 A KR1020117022604 A KR 1020117022604A KR 20117022604 A KR20117022604 A KR 20117022604A KR 20110128898 A KR20110128898 A KR 20110128898A
Authority
KR
South Korea
Prior art keywords
thiazol
pyrimidin
acetamide
tetrahydrofuro
dioxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020117022604A
Other languages
English (en)
Korean (ko)
Inventor
사친 순다르랄 샤우다리
아브라함 토마스
니샤 파락 파틸
네엘리마 카이라트카르-조쉬
인드라닐 무코파디아이
Original Assignee
그렌마크 파머수티칼스 에스. 아.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42780205&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20110128898(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 그렌마크 파머수티칼스 에스. 아. filed Critical 그렌마크 파머수티칼스 에스. 아.
Publication of KR20110128898A publication Critical patent/KR20110128898A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020117022604A 2009-03-23 2010-03-22 Ｔｒｐａ1 조절자로서 푸로피리미딘디온 유도체 Withdrawn KR20110128898A (ko)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
IN665/MUM/2009 2009-03-23
IN665MU2009 2009-03-23
US17135509P 2009-04-21 2009-04-21
US61/171,355 2009-04-21
IN2213MU2009 2009-09-23
IN2213/MUM/2009 2009-09-23
US25199409P 2009-10-15 2009-10-15
US61/251,994 2009-10-15
IN2906/MUM/2009 2009-12-16
IN2906MU2009 2009-12-16
US29447010P 2010-01-12 2010-01-12
US61/294,470 2010-01-12

Publications (1)

Publication Number Publication Date
KR20110128898A true KR20110128898A (ko) 2011-11-30

Family

ID=42780205

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020117022604A Withdrawn KR20110128898A (ko) 2009-03-23 2010-03-22 Ｔｒｐａ1 조절자로서 푸로피리미딘디온 유도체
KR1020117022603A Expired - Fee Related KR101524337B1 (ko) 2009-03-23 2010-03-23 Ｔｒｐａ1 조절자로서 티에노피리미딘디온 유도체

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020117022603A Expired - Fee Related KR101524337B1 (ko) 2009-03-23 2010-03-23 Ｔｒｐａ1 조절자로서 티에노피리미딘디온 유도체

Country Status (22)

Country Link
US (4) US20120178766A1 (https=)
EP (3) EP2411395B1 (https=)
JP (2) JP2012521406A (https=)
KR (2) KR20110128898A (https=)
CN (3) CN102361874A (https=)
AP (1) AP2948A (https=)
AU (2) AU2010227225A1 (https=)
BR (2) BRPI1013705A2 (https=)
CA (2) CA2756535A1 (https=)
DK (3) DK2411395T3 (https=)
EA (2) EA201190138A1 (https=)
ES (3) ES2424341T3 (https=)
HU (1) HUE024538T2 (https=)
IL (2) IL215175A (https=)
MX (1) MX2011009822A (https=)
PE (2) PE20120834A1 (https=)
PL (3) PL2411395T3 (https=)
PT (3) PT2411395E (https=)
SG (4) SG174398A1 (https=)
SI (3) SI2411395T1 (https=)
WO (2) WO2010109329A1 (https=)
ZA (2) ZA201107650B (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP3280A (en) 2009-03-23 2015-05-31 Glenmark Pharmaceuticals Sa Fused pyrimidine-dione derivatives as TRPA1 modulators
PT2411395E (pt) 2009-03-23 2013-06-06 Glenmark Pharmaceuticals Sa Derivados de furopirimidinadiona como moduladores de trpa1
JP5694560B2 (ja) 2010-12-20 2015-04-01 グレンマーク ファーマシューティカルズ， エセ．アー． Ｔｒｐａ１アンタゴニストとしての２−アミノ−４−アリールチアゾール化合物
EP2520566A1 (en) 2011-05-06 2012-11-07 Orion Corporation New Pharmaceutical Compounds
JP2014517031A (ja) 2011-06-13 2014-07-17 グレンマーク ファーマシューティカルズ， エセ．アー． Ｔｒｐａ１アンタゴニストを使用した呼吸器疾患の治療
JP2014517062A (ja) * 2011-06-22 2014-07-17 グレンマーク ファーマシューティカルズ， エセ．アー． ＴＲＰＡ１アンタゴニスト及びβ２アゴニストを含む医薬組成物
WO2012176105A1 (en) 2011-06-22 2012-12-27 Glenmark Pharmaceuticals Sa Pharmaceutical composition comprising a trpa1 antagonist and a leukotriene receptor antagonist
US20140148423A1 (en) * 2011-07-25 2014-05-29 Glenmark Pharmaceuticals S.A. Pharmaceutical composition comprising a trpa1 antagonist and a steroid
EP2787991A1 (en) 2011-12-05 2014-10-15 Glenmark Pharmaceuticals S.A. Pharmaceutical composition comprising a trpa1 antagonist and an anticholinergic agent
MY165622A (en) * 2012-06-08 2018-04-18 Glenmark Pharmaceuticals Sa Amides of 2-amino-4aryl thiazole compounds and their salts
PL2903965T3 (pl) 2012-10-01 2017-08-31 Orion Corporation Pochodne n-prop-2-ynylokarboksamidu i ich zastosowanie jako antagonistów trpa1
EP3010489A1 (en) * 2013-06-20 2016-04-27 Glenmark Pharmaceuticals S.A. Nanoparticulate formulation comprising a trpa1 antagonist
AU2014335868A1 (en) 2013-10-15 2016-05-05 Glenmark Pharmaceuticals S.A. Pharmaceutical composition comprising a trpa1 antagonist and an analgesic agent
EP3180345B1 (en) * 2014-08-11 2018-10-10 Hydra Biosciences, Inc. Thieno- and furo[2,3-d]pyrimidine-2,4[1h,3h]-dione derivatives as trpc5 modulators for the treatment of neuropsychiatric disorders
EP3180337B1 (en) * 2014-08-11 2018-10-10 Hydra Biosciences, Inc. Pyrido[3,4-d]pyrimidine-2,4(1h,3h)-dione derivatives
WO2016023831A1 (en) * 2014-08-11 2016-02-18 Hydra Biosciences, Inc. Pyrrolo[3,2-d]pyrimidine-2,4(3h,5h)-dione derivatives
JP6667093B2 (ja) * 2014-08-11 2020-03-18 ハイドラ・バイオサイエンシーズ・リミテッド・ライアビリティ・カンパニーＨｙｄｒａ Ｂｉｏｓｃｉｅｎｃｅｓ， ＬＬＣ ピリド［２，３−ｄ］ピリミジン−２，４（１Ｈ，３Ｈ）−ジオン誘導体
US10329265B2 (en) 2014-08-22 2019-06-25 Duke University TRPA1 and TRPV4 inhibitors and methods of using the same for organ-specific inflammation and itch
WO2016042501A1 (en) 2014-09-16 2016-03-24 Glenmark Pharmaceuticals S.A. Trpa1 antagonist for the treatment of pain associated to diabetic neuropathic pain
US11229628B2 (en) 2015-01-09 2022-01-25 Duke University TRPA1 and TRPV4 inhibitors and methods of using the same for organ-specific inflammation and itch
WO2017060488A1 (en) 2015-10-09 2017-04-13 Almirall, S.A. New trpa1 antagonists
WO2017064068A1 (en) 2015-10-14 2017-04-20 Almirall, S.A. New trpa1 antagonists
CN109310683A (zh) 2016-04-07 2019-02-05 杜克大学 用于消毒和麻醉的trpv4和trpa1的小分子双重抑制剂
WO2018162607A1 (en) * 2017-03-07 2018-09-13 F. Hoffmann-La Roche Ag Oxadiazole transient receptor potential channel inhibitors
CN109422749B (zh) * 2017-08-21 2023-01-24 重庆医药工业研究院有限责任公司 一种抑制单羧酸转运蛋白的嘧啶二酮衍生物
JP7612682B2 (ja) 2019-10-15 2025-01-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規なテトラゾール
JP7565439B2 (ja) * 2020-10-14 2024-10-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｔｒｐａ１阻害剤としてのテトラゾール誘導体
WO2022079091A1 (en) * 2020-10-14 2022-04-21 Boehringer Ingelheim International Gmbh Tetrazole derivatives as trpa1 inhibitors
CN116940575A (zh) * 2021-02-23 2023-10-24 深圳市康哲药业有限公司 噻吩并嘧啶二酮类化合物及其应用
CA3210965A1 (en) 2021-04-14 2022-10-20 Boehringer Ingelheim International Gmbh 3h,4h-thieno[2,3-d]pyrimidin-4-one derivatives as trpa1 inhibitors
CN114656480B (zh) * 2022-04-27 2024-01-26 成都施贝康生物医药科技有限公司 噻吩并嘧啶类化合物、异构体或盐及其制备方法和用途
CN114671875A (zh) * 2022-04-27 2022-06-28 成都施贝康生物医药科技有限公司 新型二氢嘧啶类化合物、异构体或盐及其制备方法和用途
WO2025264860A2 (en) 2024-06-18 2025-12-26 Yale University Methods of treating post-covid airway disease

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2248231A1 (de) 1972-10-02 1974-04-11 Basf Ag 3-aminoisothiazolo eckige klammer auf 3,4-d eckige klammer zu pyrimidine
SE9701398D0 (sv) 1997-04-15 1997-04-15 Astra Pharma Prod Novel compounds
SE9702001D0 (sv) * 1997-05-28 1997-05-28 Astra Pharma Prod Novel compounds
ATE253580T1 (de) * 1998-08-28 2003-11-15 Astrazeneca Ab Neue thieno(2,3-d)pyrimidindione, verfahren für ihre herstellung und ihre verwendung in der therapie
ES2193839B1 (es) * 2001-06-22 2005-02-16 Almirall Prodesfarma, S.A. Nuevos derivados de 6-fenildihidropirrolpirimidindiona.
GB0118479D0 (en) * 2001-07-28 2001-09-19 Astrazeneca Ab Novel compounds
WO2004014916A1 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc Pyrimidine fused bicyclic metalloproteinase inhibitors
EP1558607B1 (en) * 2002-10-30 2010-05-05 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of rock and other protein kinases
US6890923B2 (en) * 2002-12-16 2005-05-10 Astrazeneca Ab Compounds
AU2003290066A1 (en) 2002-12-18 2004-07-09 Novartis Ag Anktm1, a cold-activated trp-like channel expressed in nociceptive neurons
SE0300119D0 (sv) * 2003-01-17 2003-01-17 Astrazeneca Ab Novel compounds
EP1657238A4 (en) 2003-08-22 2008-12-03 Takeda Pharmaceutical CONDENSATE PYRIMIDINE DERIVATIVE AND ITS USE
WO2005077959A1 (en) * 2004-02-11 2005-08-25 Smithkline Beecham Corporation Pth agonists
US20070196866A1 (en) 2004-03-13 2007-08-23 Irm Llc Modulators of ion channel trpa1
WO2006083005A1 (ja) * 2005-02-03 2006-08-10 Takeda Pharmaceutical Company Limited 縮合ピリミジン誘導体およびその用途
JP2009503107A (ja) * 2005-08-04 2009-01-29 アポジー・バイオテクノロジー・コーポレイション スフィンゴシンキナーゼ阻害剤およびそれらの使用方法
CN101351463A (zh) * 2005-11-08 2009-01-21 欧加农股份有限公司 用于治疗trpv1相关病症的2-(苯并咪唑-1-基)-n-(4-苯基噻唑-2-基)乙酰胺衍生物
WO2007054480A1 (en) * 2005-11-08 2007-05-18 N.V. Organon 2-(benzimidazol-1-yl)-acetamide biaryl derivatives and their use as inhibitors of the trpv1 receptor
US20070105920A1 (en) * 2005-11-08 2007-05-10 Akzo Nobel N.V. 2-(Benzimidazol-1-Yl)-N-(4-phenylthiazol-2-yl) acetamide derivatives
JP5858557B2 (ja) * 2005-12-22 2016-02-10 ハイドラ バイオサイエンシズ インコーポレイテッドＨｙｄｒａ Ｂｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ． 疼痛を処置するためのｔｒｐａ１阻害剤
TW200800997A (en) 2006-03-22 2008-01-01 Astrazeneca Ab Chemical compounds
AR065081A1 (es) * 2007-01-29 2009-05-13 Xenon Pharmaceuticals Inc Compuestos de quinazolinona y pirimidona fusionados y composicion farmaceutica
JP2010530901A (ja) * 2007-06-22 2010-09-16 ハイドラ バイオサイエンシズ インコーポレイテッド 障害を治療するための方法および組成物
CN101711413B (zh) * 2007-06-25 2013-09-04 桑迪士克科技股份有限公司 具有位于存储元件之间的可单独控制的屏蔽板的非易失性存储装置
WO2010004390A1 (en) 2008-06-17 2010-01-14 Glenmark Pharmaceuticals, S.A. Quinazoline dione derivatives as trpa1 modulators
WO2009158719A2 (en) 2008-06-27 2009-12-30 Hydra Biosciences, Inc. Methods and compositions for treating disorders
UA103918C2 (en) 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
US8623880B2 (en) 2009-03-23 2014-01-07 Glenmark Pharmaceuticals S.A. Fused pyrimidine-dione derivatives as TRPA1 modulators
PT2411395E (pt) 2009-03-23 2013-06-06 Glenmark Pharmaceuticals Sa Derivados de furopirimidinadiona como moduladores de trpa1
DK2411397T3 (da) 2009-03-23 2013-08-05 Glenmark Pharmaceuticals Sa Isothiazol-pyrimidindionderivater som modulatorer af TRPA1
AR076332A1 (es) 2009-04-21 2011-06-01 Boehringer Ingelheim Int Derivados heterociclicos de 5-alquinil-piridinas, composiciones farmaceuticas que los comprenden y uso de los mismos para el tratamiento y/o prevencion del cancer, procesos inflamatorios, autoinmunes, y/o infecciones.
AR078522A1 (es) 2009-10-15 2011-11-16 Lilly Co Eli Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis
US8440710B2 (en) 2009-10-15 2013-05-14 Hoffmann-La Roche Inc. HSL inhibitors useful in the treatment of diabetes
CA2776028C (en) 2009-10-15 2015-12-01 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine compounds
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
MX2012008083A (es) 2010-01-12 2012-08-15 Ab Science Inhibidores de triazol y oxazol quinaza.
PH12012500361A1 (en) 2010-07-13 2012-01-19 Novartis Ag Oxazine derivatives and their use in the treatment of neurological disorders

Also Published As

Publication number Publication date
WO2010109334A2 (en) 2010-09-30
WO2010109334A3 (en) 2010-11-25
EP2411395B1 (en) 2013-05-29
ES2532386T3 (es) 2015-03-26
JP5612070B2 (ja) 2014-10-22
BRPI1013705A2 (pt) 2016-04-05
EP2634191A1 (en) 2013-09-04
ZA201107649B (en) 2012-07-25
EA022029B1 (ru) 2015-10-30
PT2411396E (pt) 2013-06-06
HUE024538T2 (hu) 2016-01-28
KR20120004422A (ko) 2012-01-12
AU2010227230A1 (en) 2011-09-22
DK2411396T3 (da) 2013-08-05
CA2756536C (en) 2015-10-06
MX2011009822A (es) 2012-01-25
CN102361877B (zh) 2014-05-07
US20120178766A1 (en) 2012-07-12
EP2411395A1 (en) 2012-02-01
SG174404A1 (en) 2011-10-28
AU2010227225A1 (en) 2011-09-15
HK1166074A1 (en) 2012-10-19
DK2411395T3 (da) 2013-08-05
US20150150876A1 (en) 2015-06-04
AU2010227225A2 (en) 2011-10-06
BRPI1009381B1 (pt) 2020-04-14
ES2424341T3 (es) 2013-10-01
EP2634191B1 (en) 2014-12-24
CN102361874A (zh) 2012-02-22
CN102361877A (zh) 2012-02-22
ES2424342T3 (es) 2013-10-01
PE20120834A1 (es) 2012-07-25
US20130289054A1 (en) 2013-10-31
PE20120775A1 (es) 2012-06-27
BRPI1009381B8 (pt) 2021-05-25
US8507503B2 (en) 2013-08-13
EA201190139A1 (ru) 2012-03-30
SG184769A1 (en) 2012-10-30
AP2011005889A0 (en) 2011-10-31
JP2012521407A (ja) 2012-09-13
ZA201107650B (en) 2012-07-25
AU2010227230B2 (en) 2015-11-26
HK1166073A1 (en) 2012-10-19
IL215177A0 (en) 2011-12-29
PT2634191E (pt) 2015-03-04
EP2411396A2 (en) 2012-02-01
SG184767A1 (en) 2012-10-30
CN103755720B (zh) 2016-07-06
EP2411396B1 (en) 2013-05-29
CN103755720A (zh) 2014-04-30
SI2411396T1 (sl) 2013-07-31
AP2948A (en) 2014-07-31
PT2411395E (pt) 2013-06-06
PL2634191T3 (pl) 2015-06-30
IL215175A (en) 2014-01-30
CA2756536A1 (en) 2010-09-30
CA2756535A1 (en) 2010-09-30
SI2634191T1 (sl) 2015-04-30
SI2411395T1 (sl) 2013-07-31
WO2010109329A1 (en) 2010-09-30
IL215177A (en) 2014-01-30
US20120295924A1 (en) 2012-11-22
EA201190138A1 (ru) 2013-05-30
US9474758B2 (en) 2016-10-25
DK2634191T3 (en) 2015-03-23
US8987278B2 (en) 2015-03-24
SG174398A1 (en) 2011-10-28
BRPI1009381A2 (pt) 2016-06-21
JP2012521406A (ja) 2012-09-13
AU2010227230A2 (en) 2011-10-27
PL2411395T3 (pl) 2013-10-31
KR101524337B1 (ko) 2015-05-29
IL215175A0 (en) 2011-12-29
PL2411396T3 (pl) 2013-10-31

Similar Documents

Publication Publication Date Title
EP2411395B1 (en) Furopyrimidinedione derivatives as trpa1 modulators
EP2411397B1 (en) Isothiazolo-pyrimidinedione derivatives as trpa1 modulators
US9000159B2 (en) Fused pyrimidine-dione derivatives as TRPA1 modulators
WO2011114184A1 (en) Amides of heterocyclic compounds as trpa1 inhibitors
WO2011132017A1 (en) Pyrido[3,4-d]pyrimidinyl acetamide derivatives as trpa1 modulators
HK1166074B (en) Furopyrimidinedione derivatives as trpa1 modulators
HK1166081B (en) Isothiazolo-pyrimidinedione derivatives as trpa1 modulators

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PC1203 Withdrawal of no request for examination

St.27 status event code: N-1-6-B10-B12-nap-PC1203

WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R11-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE)

R13 Change to the name of applicant or owner recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R13-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE)